Novavax Inc. filings document formal disclosures for a Nasdaq-listed biotechnology company focused on vaccine products, Matrix-M adjuvant technology and partnership-driven development. Recent 8-K reports record operating results, preliminary financial information, licensing arrangements for Matrix-M, Nuvaxovid marketing-authorization transfers, and facility-related agreements.
Proxy materials describe board matters, executive compensation, equity awards, shareholder voting items and governance procedures. The filings also identify Novavax common stock, par value $0.01 per share, as listed on The Nasdaq Global Select Market under NVAX.
Novavax Inc. director Charles W. Newton acquired common shares through an RSU-related transaction. On April 25, 2026, he exercised derivative rights linked to Restricted Stock Units (RSUs), resulting in ownership of 9,520 shares of Novavax common stock held directly after the transaction.
Each RSU represents a contingent right to receive one share of Novavax common stock. According to the grant terms, the RSUs will vest in three equal annual installments, with one-third of the RSUs scheduled to vest on each of the first three anniversaries of April 25, 2025, subject to his continued service on the company’s Board of Directors.
Bank of America Corporation filed an amendment to a Schedule 13G disclosing beneficial ownership of 6,655,398 shares of Novavax Inc. The filing states this stake represents 4.1% of the class, calculated using 162,935,945 outstanding shares as of February 16, 2026. The statement attributes shared voting power of 6,653,929 and shared dispositive power of 6,655,398 across Bank of America and specified subsidiaries.
Novavax, Inc. is asking stockholders to vote at its June 18, 2026 virtual annual meeting on director elections, executive pay and key equity plan changes. The proxy highlights 2025 results, including $1.1 billion total revenue, a 42% reduction in non‑GAAP combined R&D and SG&A expenses compared to 2024, and a year‑end cash position of $857 million.
Stockholders are being asked to elect three Class I directors, approve a non‑binding say‑on‑pay vote, and ratify Ernst & Young LLP as auditor. Novavax also seeks to add 9.4 million shares to its 2015 Stock Incentive Plan and 1 million shares to its Employee Stock Purchase Plan, while emphasizing independent board leadership, committee oversight and a performance‑linked, at‑risk executive compensation program.
Novavax, Inc. EVP of R&D Robert Edward Walker received new equity compensation awards. He was granted stock options covering 99,500 shares of common stock at an exercise price of $8.46 per share, expiring on April 14, 2036.
The option vests 25% on the first anniversary of the April 14, 2026 grant date, with the remaining 75% vesting in equal monthly installments over the following three years, subject to continued employment. He also received 66,000 restricted stock units, each representing one share of common stock, vesting in three equal annual installments over three years, also contingent on continued employment.
NOVAVAX INC executive Robert Edward Walker, EVP, R&D, filed an initial ownership report showing equity awards and common stock holdings. The filing lists stock options to purchase 11,500 shares of common stock at $6.97 expiring on March 7, 2033, 22,510 shares at $10.11 expiring on March 3, 2035, and 18,826 shares at $8.39 expiring on March 2, 2036.
He also holds restricted stock units covering 47,600, 29,490 and 26,300 shares of common stock, plus 34,386 shares of common stock directly. Footnotes describe standard vesting schedules over three to four years, tied to continued employment.
Shah Capital files Amendment No. 6 to its Schedule 13D on Novavax, Inc., updating its ownership and activist intentions. The filing shows Shah Capital Management and related entities beneficially owning up to 14,845,097 shares of Novavax common stock, or 9.11% of the company, based on shares outstanding as of February 16, 2026.
Most shares are held through Shah Capital Opportunity Fund LP, which directly owns 14,000,000 shares, while Himanshu H. Shah personally owns 125,359 shares. The amendment discloses that all shares, other than Mr. Shah’s personal holdings, were acquired using investment capital through open-market purchases.
The filing also notes an April 8, 2026 open letter from Shah Capital to Novavax’s board stating its intention to vote against board nominees and executive compensation. The letter cites concerns such as value destruction, a pessimistic 2026 revenue forecast, low institutional credibility, cost discipline and profitability, and governance changes.
The Vanguard Group amended its Schedule 13G/A to report that it beneficially owns 0 shares of Novavax Inc. common stock, representing 0% of the class.
The amendment explains an internal realignment effective January 12, 2026 and states certain subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538. The form is signed by Ashley Grim on 03/27/2026.
Novavax Inc. director John W. Shiver exercised restricted stock units and received additional common shares as part of his equity compensation. On March 10, 2026, he converted 7,947 RSUs into 7,947 shares of Novavax common stock at a price of $0.00 per share.
Following the transactions, Shiver directly holds 7,947 shares of common stock and 15,893 restricted stock units. The RSUs from this grant are scheduled to vest in three equal installments on each of the first three anniversaries of March 10, 2025, assuming he continues to serve on Novavax’s board through each vesting date.
Novavax EVP, CFO and Treasurer James Patrick Kelly reported equity award activity involving restricted stock units (RSUs) and common stock. On March 7, 2026, 12,223 RSUs were exercised and converted into 12,223 shares of Novavax common stock at a stated price of $0.0000 per share.
On the same date, 5,904 shares of common stock were withheld by the company at $9.98 per share to satisfy tax withholding obligations related to the RSU vesting, as noted in the footnotes. After these transactions, Kelly directly held 130,599 shares of Novavax common stock. A related footnote states that one-third of the RSUs from this grant vest on each of the first three anniversaries of the March 7, 2023 grant date, subject to continued employment.